Business Standard

US books 100 mn Covid-19 vaccine doses for $2.1 bn from GSK, Sanofi Pasteur

The US government has a further option for the supply of an additional 500 million doses longer term as part of its Operation Warp Speed programme

covid, coronavirus, vaccine, drug, pharma
Premium

Earlier this week the British government signed a deal for 60 million doses of a potential coronavirus vaccine that could start to be rolled out in the first half of next year.

AP | PTI London
Pharma giants GlaxoSmithKline and Sanofi Pasteur have announced they will supply 100 million doses of its experimental Covid-19 vaccine to the United States as governments buy up supplies in hopes something will work.

The United States will pay up to $2.1 billion for development including clinical trials, manufacturing, scale-up and delivery of its vaccine,'' the companies said in a statement. Sanofi will get the bulk of the funds.

The US government has a further option for the supply of an additional 500 million doses longer term as part of its Operation Warp Speed programme.

The portfolio of vaccines being assembled

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 31 2020 | 7:44 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com